Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Impact of enteral Ecoimmunonutrition on immunological response, nutritional status and tolerance to treatment in gastrointestinal malignancy patients receiving chemotherapy.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal changes in nutritional status during induction chemotherapy and their association with treatment outcomes in pediatric patients with newly diagnosed acute myeloid leukemia.Frontiers in medicine · 2026Article
- Effects of whole cycle nutrition management based on "Hospital to Home (H2H)" model on nutritional status and immune function of patients with gastrointestinal tumor chemotherapy.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeGastrointestinal (GI) malignancies are major contributors to global cancer-related mortality, with many patients experiencing severe nutritional decline and immune suppression due to chemotherapy. Enteral immunonutrition (EIN), which includes immune-modulating nutrients, has shown promise in improving nutrition, reducing chemotherapy-related side effects, and enhancing immune function, but its role in advanced GI cancer patients undergoing chemotherapy is not well-studied.
methodsThis randomized, controlled study involved 28 patients with advanced GI malignancies, assigned to either standard nutrition or EIN for 42 days. Key measures included nutritional status, immune markers, quality of life (QoL), and chemotherapy-related toxicities. The study also used a preclinical mouse model to evaluate EIN's impact on tumor growth and intestinal health during chemotherapy.
resultsPatients in the EIN group demonstrated significantly improved serum albumin levels on day 28 (P = 0.03) and a higher CD4 + /CD8 + T-cell ratio on day 42 (P < 0.01) compared to controls. EIN supplementation significantly mitigated chemotherapy-induced fatigue and improved QoL scores on days 28 and 42 (P < 0.05). Repeated measures analysis revealed a substantial reduction in pro-inflammatory cytokines (IL-1, IL-6) and an increase in the anti-inflammatory cytokine IL-10 in the EIN group (P < 0.05). Preclinical findings showed that EIN significantly reduced tumor volume (P < 0.05) and preserved the integrity of the intestinal mucosal barrier, evidenced by higher ZO-1 and Occludin expression (P < 0.05).
conclusionThese findings suggest that EIN during chemotherapy enhances nutritional and immune status, reduces inflammation, and improves QoL, warranting further large-scale trials to confirm its benefits in cancer care.
trial registrationThis trial was registered on the Chinese Clinical Trial Register (ChiCTR2400084224) on 13-05-2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.